Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IDL Diagnostics ABOSTO:IDLDX +3.69%55 Current Ratio is 3.49 as of Mar. 2026, which is 47% below its 10-year median of 6.56. GuruFocus rates OSTO:IDLDX with a GF Score™ of 55/100 and a GF Value™ of kr0.54 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, IDL Diagnostics AB ranks better than 76.06% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. IDL Diagnostics AB's current ratio for the quarter that ended in Mar. 2026 was 3.49.
IDL Diagnostics AB has a current ratio of 3.49. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for IDL Diagnostics AB's Current Ratio or its related term are showing as below:
OSTO:IDLDX'
s Current Ratio Range Over the Past 10 Years
Min: 1.47 Med: 6.56 Max: 17.63
Current: 3.49
During the past 13 years, IDL Diagnostics AB's highest Current Ratio was 17.63. The lowest was 1.47. And the median was 6.56.
OSTO:IDLDX's Current Ratio is ranked better than 76.06% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.1
vs OSTO:IDLDX: 3.49
IDL Diagnostics AB (OSTO:IDLDX) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
IDL Diagnostics AB Current Ratio Related Terms
IDL Diagnostics AB Current Ratio Historical Data
* Premium members only.
The historical data trend for IDL Diagnostics AB's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:IDLDX vs TMO, DHR, IDXX: Current Ratio Comparison
For the Diagnostics & Research subindustry, IDL Diagnostics AB's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IDL Diagnostics AB Current Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, IDL Diagnostics AB's Current Ratio distribution charts can be found below:
* The bar in red indicates where IDL Diagnostics AB's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IDL Diagnostics AB (OSTO:IDLDX) has a Current Ratio of 3.49 as of Mar. 2026. This is 47% below median its historical median of 6.56. Over the past decade, IDL Diagnostics AB's Current Ratio has ranged from 1.47 to 17.63. According to the industry distribution chart, IDL Diagnostics AB ranks #51 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 23.9%.
Is IDL Diagnostics AB's Current Ratio too high?
IDL Diagnostics AB's current Current Ratio of 3.49 is 47% below median its 10-year median of 6.56. Over the past 10 years, this metric has ranged from a low of 1.47 to a high of 17.63. The Medical Diagnostics & Research industry median Current Ratio is 2.10. IDL Diagnostics AB's value of 3.49 is 66.2% above this industry median. Based on the distribution chart, IDL Diagnostics AB ranks #51 out of 213 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, IDL Diagnostics AB has a GF Score™ of 55/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IDL Diagnostics AB's Current Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, IDL Diagnostics AB ranks #51 out of 213 companies for Current Ratio. This places IDL Diagnostics AB in the top 24% of its industry — outperforming the majority of peers. The industry median Current Ratio is 2.10. IDL Diagnostics AB's value of 3.49 is 66.2% above this benchmark. Historically, IDL Diagnostics AB's own Current Ratio has ranged from 1.47 to 17.63 over the past decade. While the company's 10-year median is 6.56 vs. the industry median of 2.10, IDL Diagnostics AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Diagnostics & Research company?
The median Current Ratio among Medical Diagnostics & Research companies is 2.10, based on 213 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IDL Diagnostics AB's current Current Ratio of 3.49 is 66.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median Current Ratio is 2.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IDL Diagnostics AB's current Current Ratio is 3.49, which is 47% below median its own 10-year median of 6.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDL Diagnostics AB stock overvalued right now?
Based on GuruFocus' analysis, IDL Diagnostics AB (OSTO:IDLDX) is currently considered Modestly Undervalued. The stock's GF Value™ is kr0.54, compared to a current price of kr0.42 — trading 21.9% below its estimated fair value. The current Current Ratio is 3.49, which is 47% below median its 10-year median of 6.56 and 66.2% above the Medical Diagnostics & Research industry median of 2.10. IDL Diagnostics AB's overall GF Score™ is 55/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For IDL Diagnostics AB (OSTO:IDLDX), the current Current Ratio is 3.49 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IDL Diagnostics AB (OSTO:IDLDX) Overvalued in 2026?
Based on GuruFocus' analysis, IDL Diagnostics AB stock appears to be undervalued.
The current stock price of kr0.42 is trading 21.9% below its estimated GF Value™ of kr0.54.
GuruFocus considers IDL Diagnostics AB to be Modestly Undervalued.
Key valuation signals for OSTO:IDLDX:
Current Ratio: 3.49 (47% below median its 10-year median of 6.56)
GF Value™: kr0.54 vs. price of kr0.42 (21.9% below fair value)
Industry Position: 66.2% above the Medical Diagnostics & Research median (#51 of 213)
No single metric tells the full story. See the OSTO:IDLDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IDL Diagnostics AB is a Swedish company that develops and markets blood and urine sample tests. It specializes in oncology and bacteriology. The company has a broad product portfolio, is used in healthcare, and is established in various markets. In oncology, IDL Diagnostics uses various biomarkers, TK1 and cytokeratins, to support the treatment of cancers such as breast, prostate, and bladder cancers.
55GF Score
Get the complete analysis for OSTO:IDLDX
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:IDLDX has been successfully added to your 
